Joi Irving, MD
Internal Medicine · Union, MONPI 1457508665
Payments from drug & device makers
Across 202 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$706
- Novo Nordisk$443
- Amgen$294
- Lilly USA, LLC$279
- Novartis$171
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,03599%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $1,039 |
| Boehringer Ingelheim | 17 | $706 |
| Novo Nordisk | 23 | $443 |
| Amgen | 20 | $294 |
| Lilly USA, LLC | 16 | $279 |
| Novartis | 6 | $171 |
| Sanofi-aventis U.S. LLC | 11 | $170 |
| Pfizer | 8 | $131 |
| GSK | 8 | $126 |
| AstraZeneca | 8 | $109 |
| Abbott | 5 | $90 |
| Supernus Pharmaceuticals, Inc. | 5 | $81 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Merck | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Bayer | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Exact Sciences | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$4,065 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $100,240 |
| TrulicityDulaglutide | 48 | $81,741 |
| MounjaroTirzepatide | 59 | $68,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $43,100 |
| EliquisApixaban | 58 | $37,034 |
| JardianceEmpagliflozin | 27 | $30,074 |
| Nurtec OdtRimegepant Sulfate | 19 | $29,110 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $29,093 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $25,947 |
| LinzessLinaclotide | 20 | $22,972 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $22,519 |
| FarxigaDapagliflozin Propanediol | 25 | $21,296 |
| XareltoRivaroxaban | 25 | $18,613 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,259 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $279 | $150,523107 claims |
| Novo NordiskOzempic | $443 | $100,24069 claims |
| PfizerEliquis, Nurtec Odt | $131 | $66,14477 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $706 | $62,69367 claims |
| GSKTrelegy Ellipta | $126 | $43,10059 claims |
| AstraZenecaFarxiga, Symbicort | $109 | $27,88950 claims |
| AbbVieLinzess | $1,039 | $22,97220 claims |
| Johnson & JohnsonXarelto | $14 | $18,61325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Union
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.